- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02473016
Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
November 16, 2017 updated by: Capnia, Inc.
A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles (UCLA)
-
-
Florida
-
Tampa, Florida, United States, 33634
- Meridien Research
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsbugh Medical Center (UPMC)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina (MUSC)
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female, 18 years of age and older.
- History of classical trigeminal neuralgia with or without persistent background facial pain, not secondary, as defined by International Classification of Headache Disorders (ICHD), third edition, beta version (ICHD-3 beta, Cephalalgia 2013).
- Diagnosis of trigeminal neuralgia (TN) for at least 60 days prior to enrollment.
- Experience pain with a score of at least 5 on a 0-10 scale during a typical TN episode as reported by subject. Note: Prior to treatment pain score must a 5 or greater on a VAS.
- History of unilateral typical TN pain predominantly in the V2 branch of the trigeminal nerve.
- Absence of a significant structural lesion (e.g., a tumor) as the cause of pain as shown in at least one neuro-imaging study.
- On stable dose of all medications, including those for the treatment of TN prevention/prophylaxis, for at least 14 days prior to baseline (including, but not limited to, verapamil, lithium, melatonin, any anticonvulsant, any systemic corticosteroid or steroid injection, occipital nerve block, other cranial or extracranial nerve block, or any neurostimulation treatment). Note: Subjects are allowed to use their usual standard of care for the acute/abortive treatment of trigeminal neuralgia attacks 60 or more minutes after the initial dose, provided it is approved by the investigator.
- Capable of completing a diary.
- Able to provide written Informed Consent.
Exclusion Criteria:
- Are unable to comply with protocol requirements.
- Have recent of alcohol or drug abuse within 2 years prior to study enrollment.
- Current major psychiatric disorder: suicidal ideation, bipolar, panic disorder, schizophrenic, or psychosis. Subjects who are documented as clinically stable and not exhibiting symptoms related to their psychiatric disorder are eligible.
- History of asthma (other than mild or intermittent).
- Have an existing serious unstable systemic disease (e.g., severe emphysema, other respiratory diseases, heart disease, etc.) that precludes participation.
- Clinically significant nasal disorder (deviated septum, presence of polyps, evidence of significant congestion, rhinitis, or other nasal abnormalities) that prevents unrestricted breathing through each nostril.
- Currently on anticoagulants or have a diagnosis of a bleeding disorder.
- Current diagnosis of fibromyalgia, temporomandibular disorders (TMD), odontogenic pain or other orofacial pain.
- Surgery for treatment of TN within 30 days prior to screening. Note: Investigator must ensure that patients who have had surgery have recovered and are not experiencing any side effects from surgery for treatment of TN
- Females who are pregnant or breast-feeding and/or plan to become pregnant or to breast-feed during study participation or within 30 days after treatment.
- Participation in a previous study with nasal CO2.
- Participation in another investigational drug study within 30 days prior to randomization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo.
This is a single-blind study so subjects will not know the order.
Subjects will receive 3 doses of active and 3 doses of placebo.
One dose is a 60 second delivery of CO2 or placebo.
At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
|
Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain relief assessed on a visual analog scale (VAS) in a subject diary
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of subjects experiencing pain freedom at 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary
Time Frame: Assessed through 60 minutes post intial dose
|
Assessed through 60 minutes post intial dose
|
Reduction in the number of attacks (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Increase in duration between episodes of pain (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Percentage of subjects with pain relief 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary
Time Frame: Assessed through 60 minutes post intial dose
|
Assessed through 60 minutes post intial dose
|
Rescue medication usage (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Subject satisfaction (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Attack recurrence (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Decreased trigger sensitivity (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Reported Adverse Events (recorded in a subject diary and during follow up phone calls)
Time Frame: Up to 7 days after inital dose
|
Up to 7 days after inital dose
|
Reduction in intensity of attacks (recorded in a subject diary)
Time Frame: Assessed through 24 hours from initial dose
|
Assessed through 24 hours from initial dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
April 1, 2017
Study Registration Dates
First Submitted
May 29, 2015
First Submitted That Met QC Criteria
June 12, 2015
First Posted (Estimate)
June 16, 2015
Study Record Updates
Last Update Posted (Actual)
November 17, 2017
Last Update Submitted That Met QC Criteria
November 16, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trigeminal Neuralgia
-
Klinikum Klagenfurt am WörtherseeUniversity of KlagenfurtCompletedGlossopharyngeal Neuralgia | Trigeminal Neuralgia, Idiopathic | Postherpetic; Neuralgia, Trigeminal (Etiology) | Atypical Facial PainAustria
-
University of FloridaFacial Pain Research FoundationCompleted
-
Beijing Tiantan HospitalCompletedTrigeminal Neuralgia, SecondaryChina
-
Beijing Tiantan HospitalNot yet recruitingPRP | Trigeminal Neuralgia, Idiopathic
-
BiogenCompletedTrigeminal Neuralgia (TN) | Other Neuropathic PainUnited States
-
Ziekenhuis Oost-LimburgCompletedTrigeminal Neuralgia (TN)Belgium
-
Shifa Clinical Research CenterCompletedTrigeminal Neuralgia, Idiopathic
-
Vanderbilt University Medical CenterCompletedTrigeminal NeuralgiaUnited States
-
Beijing Tiantan HospitalBeijing Friendship Hospital; Beijing Ditan HospitalCompletedIdiopathic Trigeminal NeuralgiaChina
-
Seoul National UniversityRecruitingFacial Pain | Cluster Headache | Trigeminal Neuralgia | Postherpetic NeuralgiaKorea, Republic of
Clinical Trials on Carbon Dioxide Drug Delivery System (CDDS)
-
Sheba Medical CenterKaplan Medical Center; The Baruch Padeh Medical Center, PoriyaUnknownFemale Stress Urinary Incontinence
-
Kaiser Clinic and HospitalCompletedObesity | Dilatation of Anastomosis | Bypass ComplicationBrazil
-
University of California, IrvineUniversity of Minnesota; Reliant Technologies, Inc. Mountain View, CACompleted
-
Massachusetts General HospitalTerminatedActinic Keratosis | Extensive Photodamage | History of Numerous Skin CancersUnited States
-
Ottawa Heart Institute Research CorporationTerminated
-
University of MichiganCompleted
-
Inonu UniversityCompletedMorbid Obesity | Bariatric Surgery Candidate | Hemodynamic InstabilityTurkey
-
QLT Inc.TerminatedProstatic HyperplasiaUnited States, Canada
-
University Hospital, GasthuisbergCompletedLaparoscopic HysterectomyBelgium
-
Spire, Inc.Clinimark, LLCCompleted